Navigation Links
Drug for Acute Respiratory Distress May Do More Harm Than Good: Study
Date:12/12/2011

SUNDAY, Dec. 11 (HealthDay News) -- A study assessing intravenous infusion of the drug salbutamol in patients with acute respiratory distress syndrome was halted because the treatment did not improve patient outcomes and was associated with an increased risk of death, researchers say.

Acute respiratory distress syndrome (ARDS) occurs in about 14 percent of patients who require being placed on mechanical ventilation. The death rate among patients with ARDS is high -- 40 to 60 percent -- and survivors have a substantial decrease in their quality of life.

However, "routine use of [beta-2] agonist therapy in mechanically ventilated patients with ARDS cannot be recommended," the researchers wrote in an article published in the Dec. 12 online edition of The Lancet.

The British study included 326 patients who received either salbutamol (also known as albuterol) or a placebo within 72 hours of developing ARDS, and the treatment continued for up to seven days. But the study was stopped after 55 (34 percent) of the 161 patients in the salbutamol group died, compared with 38 (23 percent) of the 163 patients in the placebo group.

Overall, the death rate was 47 percent higher in the salbutamol group than in the placebo group, the report indicated.

In addition, patients in the salbutamol group had fewer ventilator-free days and organ failure-free days than those in the placebo group.

"Our findings show that intravenous salbutamol given to patients with early ARDS significantly increased 28-day mortality, and reduced ventilator-free days and duration of organ support compared with those given placebo," Fang Gao Smith and Gavin Perkins of the University of Warwick, and colleagues, explained in a journal news release.

The authors added that the therapy was "poorly tolerated" by patients because it was linked to heart rhythm abnormalities and lactic acidosis (a dangerous buildup of lactic acid in the blood). "These findings were unexpected," the researchers noted.

The findings of the cancelled study may be sufficient to change treatment of patients with ARDS, Dr. B. Taylor Thompson, of Massachusetts General Hospital and Harvard Medical School, wrote in an accompanying editorial.

"[Beta-2] agonist treatment in patients with ARDS should be limited to the treatment of clinically important reversible airway obstruction and should not be part of routine care," Thompson recommended.

More information

The U.S. National Heart, Lung, and Blood Institute has more about acute respiratory distress syndrome.

-- Robert Preidt

SOURCE: The Lancet, news release, Dec. 11, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Few With Acute Kidney Injury See Specialists, Study Finds
2. TAST 2011 -- Thrombolysis and Acute Stroke Treatment in 2011: Preparing for the next decade
3. Dendritic cells protect against acute pancreatitis
4. FDA funds Rochester researchers to give chronic and acute pain clinical trials a makeover
5. Unsaturated fat breakdown leads to complications of acute pancreatitis in obese patients
6. Miriam Hospital researchers pilot new acute hepatitis C screening strategy for HIV-infected patients
7. Death Rate Higher in Minorities With Acute Leukemia
8. Regional differences in the care of acute stroke patients
9. Alcohol consumption in relation to acute pancreatitis
10. Drinking just 1 measure of spirits increases the risk of acute pancreatitis
11. $12 million NIH grant to study acute lung injury
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug for Acute Respiratory Distress May Do More Harm Than Good: Study
(Date:1/19/2017)... ... ... With the cold weather here, many people will have to clear snow with snow blowers ... of snow, but they can be dangerous when used incorrectly. That’s why Amica Insurance ... proper use of snow blowers:, , When removing wet snow or ...
(Date:1/19/2017)... ... ... Cosmetic Town, an online plastic surgery community, begins 2017 with an update ... their readers to get the information they desire. The procedures are now listed according ... on those particular areas. , “We are excited to streamline our listings in a ...
(Date:1/19/2017)... ... 2017 , ... Bio-Optronics Inc. is proud to announce the ... to seamlessly integrate and streamline the way researchers prepare and conduct patient visits. ... and improving efficiency significantly for users – a first in the CTMS industry. ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... staff members in 2017 who are passionate about making a difference in the ... and headquartered in Tampa, UMA, a nonprofit healthcare educational institution, has more than ...
(Date:1/19/2017)... ... 2017 , ... For the third year running, Noto Insurance ... surrounding area, is inaugurating a charity event to help raise funds for ... Gehrig's disease or motor neurone disease, is a deadly neurological disorder that affects ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)...   Science Exchange , the leading marketplace ... the first five replication studies from the ... in eLife today. Despite intense scrutiny around reproducibility ... evaluation of reproducibility rates that may identify specific ... assessments of reproducibility, the results of this project ...
(Date:1/19/2017)... January 18, 2017 , , Marks E-QURE ... distribution agreement, following similar agreements in Israel ... Wound care is $2 5 billion ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of ... Médica Equipos Médicos S.A.S. (TeckMedica) in Colombia for the ...
(Date:1/19/2017)... , Jan. 18, 2017 The drug ... billion by 2021 from USD 1,179.20 billion in 2016, ... Increasing prevalence of chronic diseases, increasing demand for ... factors driving the growth of this market. Whereas, self-administration ... generic drugs offer significant growth opportunities for players operating ...
Breaking Medicine Technology: